

Circassia: Consumption, Demand, Sales, Competitor and Forecast 2016 – 2021

Circassia Global Market 2016 Analysis and Forecast to 2021

PUNE, INDIA, September 23, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development by [Circassia Pharmaceuticals Plc](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Complete Report @

<https://www.wiseguyreports.com/reports/649764-circassia-pharmaceuticals-plc-product-pipeline-review-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/649764-circassia-pharmaceuticals-plc-product-pipeline-review-2016>

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Circassia Pharmaceuticals Plc
- The report provides overview of Circassia Pharmaceuticals Plc including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-



registration till discovery and undisclosed stages

- The report assesses Circassia Pharmaceuticals Plc's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Circassia Pharmaceuticals Plc's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Circassia Pharmaceuticals Plc's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Circassia Pharmaceuticals Plc
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Circassia Pharmaceuticals Plc's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Have any query @ <https://www.wiseguyreports.com/enquiry/649764-circassia-pharmaceuticals-plc-product-pipeline-review-2016>

Key Points from Table of Content

Circassia Pharmaceuticals Plc - Research and Development Overview 6

Key Therapeutic Areas 6

Circassia Pharmaceuticals Plc - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Combination Treatment Modalities 11

Circassia Pharmaceuticals Plc - Pipeline Products Glance 12

Circassia Pharmaceuticals Plc - Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

Circassia Pharmaceuticals Plc - Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

Circassia Pharmaceuticals Plc - Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Circassia Pharmaceuticals Plc - Drug Profiles 16

Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

glycopyrronium bromide 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

Vaccine for Asthma and Ragweed-Induced Rhinoconjunctivitis 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

Vaccine for Birch Pollen Allergy 20

Product Description 20

Mechanism of Action 20
R&D Progress 20
Vaccine for House Dust Mite Induced Allergic Rhinoconjunctivitis 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
(fluticasone propionate + glycopyrronium bromide + salmeterol xinafoate) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Vaccine for Japanese Cedar Pollen Allergy 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
(Inhaled Corticosteroid + Long-acting Muscarinic Antagonist) 25
Product Description 25
Mechanism of Action 25

Buy now @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=649764 □

Continued...

Contact Us:
NORAH TRENT
Partner Relations & Marketing Manager
sales@wiseguyreports.com
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK) □

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.